An important lesson for vaccine design
Published today in PLOS Medicine, the study was made possible by a partnership between the University of Sydney, Kids Research, Sydney Children’s Hospitals Network, the Kirby Institute at UNSW Sydney, Australian Red Cross Lifeblood, St Vincent’s Hospital and NSW Health Pathology, as well as other local and international collaborators.
The team analysed the serum of 233 individuals diagnosed with COVID-19 over 7 months and uncovered that the level of immunity over time is dependent on disease severity and the viral variant. They show that antibodies developed during the first wave had reduced effectiveness against six variants, ranging from those observed in the second wave in Australia through to three variants of concern that have driven the global pandemic in the UK, Brazil and South Africa.
How do we study the immune response?
The serum of COVID-19 infected individuals was of interest as it is the part of our blood that contains crucial information about our immune system. Analysis of the serum made it possible to create a detailed timeline of the level of ‘neutralising antibodies’ produced against COVID-19 infection, and so to see if there was long-term immunity.
Neutralising antibodies are part of our immune system’s frontline arsenal that is triggered during infection and vaccination. Their job is to shield cells that are usually the target of a pathogen (such as the SARS-CoV-2 virus which causes the COVID-19 disease) from being infected. The level of neutralising antibody response can be a defining feature of how effectively our body fights off illness.
Interestingly, a rare group of ‘super responders’ was also identified as an exception.
This group of ‘super responders’ had a stable and robust level of antibodies across all COVID-19 variants. The researchers say this group could prove useful for investigating the potential of convalescent plasma (using blood from people who have recovered to treat others) which has so far proven ineffective against severe COVID-19 illness. In addition, key donors could be looked at closely and their antibodies cloned for future therapeutic use.
Why it is important?
Co-senior author Associate Professor Fabienne Brilot of the University of Sydney and Kids Research, Sydney Children’s Hospitals Network, and her research team led the analysis branch of the study, using highly sensitive tools they developed to study the antibodies in detail.
“We can learn a great deal from these people who were infected in the first wave in Australia as they were infected with the same variant that our current vaccines are based on,” said Associate Professor Brilot.
“While the approved vaccines are showing good responses, our study highlights the importance of continued vaccine development, especially taking into account the differences in variants.”
Co-senior author Associate Professor Stuart Turville of the Kirby Institute said the study was conducted to investigate the level, breadth and longevity of the immunity generated from COVID-19 infection and whether mutation of the virus compromises immunity.
“What this work has shown us is that current observations about vaccines show they offer a much broader protection against COVID-19 and its variants than the body’s natural immune response following infection, which is usually only protective against the variant of the virus that the person was infected with. We, therefore, should not rely on the body’s natural immune response to control this pandemic, but rather the broadly protective vaccines that are available.”
News
Hundreds of AI tools have been built to catch covid – None of them helped
When covid-19 struck Europe in March 2020, hospitals were plunged into a health crisis that was still badly understood. “Doctors really didn’t have a clue how to manage these patients,” says Laure Wynants, an [...]
Two doses of Pfizer, AstraZeneca COVID-19 shots effective against delta variant, study finds
Pfizer found to be 88 per cent effective at preventing symptomatic disease from delta variant. Two doses of Pfizer-BioNTech or AstraZeneca-Oxford's COVID-19 vaccines are nearly as effective against the highly transmissible delta coronavirus variant [...]
S.Africa’s Aspen releases first batch of Johnson vaccine
South African pharmaceutical company Aspen said Monday it was releasing its first batch of African-produced COVID-19 vaccines under a licensing deal with the US giant Johnson & Johnson. The Durban-based company said the first [...]
COVID-19 Variants: What the Future Could Look Like After the Pandemic
Since the coronavirus pandemic shut down the world, scientists have clamored to develop vaccines to prevent the spread and medicines that will cure the sick. But a virus’ main goal is to replicate and [...]
Delta variant of SARS-CoV-2 will likely be dominant strain globally within months
The highly transmissible delta variant of SARS-CoV-2, the coronavirus causing the disease COVID-19, is now present in 124 countries and will become the dominant strain globally in the coming months as it is outcompeting [...]
UK scientists back Covid boosters as study finds post-jab falls in antibodies
Scientists have backed proposals for Covid boosters in the autumn after blood tests on hundreds of people revealed that protective antibodies can wane substantially within weeks of second vaccine shots being given. Falls in [...]
Pfizer-BioNTech and Moderna COVID-19 vaccines establish recall responses to reinfection
Researchers in the United States have conducted a study showing that the coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna generate a coordinated adaptive immune response that is capable of eliciting recall [...]
Study shows new ‘warm vaccine’ effective against all key virus variants
CSIRO, Australia's national science agency, played an important role in evaluating heat-tolerant COVID-19 vaccine formulations developed by the Indian Institute of Science (IISc) and biotech start-up Mynvax—against all current SARS-CoV-2 variants of concern. Published [...]
Podcast – Nanovisaging 2040 How Synergies between Nanotechnology, Nanomedicine, and AI might Benefit Humanity
Frank Boehm (NanoApps Medical Inc. Founder) in discussion with Nana Kay in a Wealth Secrets podcast. EP 19. Nanovisaging 2040. From Nana Kay: Nanovisaging 2040: How Synergies between Nanotechnology, Nanomedicine, and AI might Benefit [...]
Data in favour of mixing COVID-19 vaccines, but long-term effects unknown
Canada, like several other countries, has been mixing and matching COVID-19 vaccines for weeks amid safety concerns over the AstraZeneca shot. On Monday, the chief scientist at the World Health Organization (WHO) cautioned against that approach, calling [...]
CRISPR stops coronavirus replication in human cells
Scientists have harnessed CRISPR gene-editing technology to block the replication of the novel coronavirus in human cells — an approach that could one day serve as a new treatment for COVID-19. However, the study was performed [...]
Controlling the Size of Nanoparticles
Depositing nanoparticles using the NL50 is now simpler than ever with the pre-loaded optimized recipes for a variety of frequently used materials, including Au, Ag, Pt and Cu. These optimized recipes generate high-quality nano-coatings [...]
Shape of Nanoparticles in Body Fluids – a Biomarker for Identifying Cancer Types?
A recent study by scientists from Japanese universities has shown that the shape of cell-derived nanoparticles, known as "extracellular vesicles" (EVs), in body fluids could be a biomarker for identifying types of cancer. In [...]
Study reveals how our immune system reacts to COVID-19 variants
An important lesson for vaccine design Australian scientists researching how our immune system responds to COVID-19 have revealed that those infected by early variants in 2020 produced sustained antibodies, however, these antibodies are not [...]
COVID-19: What you need to know about the coronavirus pandemic on 8 July
1. How COVID-19 is affecting the globe Confirmed cases of COVID-19 have passed 185 million globally, according to Johns Hopkins University. The number of confirmed deaths stands at more than 4 million. More than 3.29 [...]
Here’s what you should know about the Lambda variant
The World Health Organization (WHO) has added another COVID strain to its list of coronavirus variants to keep an eye on: the COVID-19 Lambda variant. This particular variant has now spread to more than two dozen [...]
